BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Samsung Bioepis stepping into EU market with Enbrel biosimilar
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Samsung Bioepis stepping into EU market with Enbrel biosimilar
Jan. 20, 2016
By
Haky Moon
and
Cornelia Zou
No Comments
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. got the first EU approval for biosimilar etanercept, a win that opens up the European market for a company that is working to become a global top-tier biosimilar maker.
BioWorld Asia